MD20140122A2 - Procedee de producere a clorhidratului de anamorelin cu un conţinut controlat de clorură - Google Patents

Procedee de producere a clorhidratului de anamorelin cu un conţinut controlat de clorură

Info

Publication number
MD20140122A2
MD20140122A2 MDA20140122A MD20140122A MD20140122A2 MD 20140122 A2 MD20140122 A2 MD 20140122A2 MD A20140122 A MDA20140122 A MD A20140122A MD 20140122 A MD20140122 A MD 20140122A MD 20140122 A2 MD20140122 A2 MD 20140122A2
Authority
MD
Moldova
Prior art keywords
chloride content
methods
controlled chloride
anamorelin hydrochloride
producing
Prior art date
Application number
MDA20140122A
Other languages
English (en)
Russian (ru)
Other versions
MD4615B1 (ro
MD4615C1 (ro
Inventor
Син-Ицу КУВАБЭ
Такэхико ЯНАГИМА-ТИ
Хидэюки ЁСИЯМА
Симон ПАЙНС (покойный)
ГРУТ Элинор ДЕ
РУБИО Силвина ГАРСИЯ
Питер Манини
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20140122(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MD20140122A2 publication Critical patent/MD20140122A2/ro
Publication of MD4615B1 publication Critical patent/MD4615B1/ro
Publication of MD4615C1 publication Critical patent/MD4615C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Invenţia se referă la forme ale monoclorhidratului de anamorelin sub formă de particule fine sau la o compoziţie care conţine monoclorhidrat de anamorelin având un conţinut de clorură controlat, de preferinţă izolat în stare amorfă şi/sau sub formă de particule fine, precum şi la procedee de fabricare a formelor menţionate.De asemenea, sunt descrise compoziţii farmaceutice care conţin formele sus-menţionate.
MDA20140122A 2012-04-20 2013-04-18 Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine MD4615C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Publications (3)

Publication Number Publication Date
MD20140122A2 true MD20140122A2 (ro) 2015-05-31
MD4615B1 MD4615B1 (ro) 2019-01-31
MD4615C1 MD4615C1 (ro) 2019-08-31

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140122A MD4615C1 (ro) 2012-04-20 2013-04-18 Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine

Country Status (47)

Country Link
US (8) US20140018391A1 (ro)
EP (3) EP2838892B1 (ro)
JP (3) JP6109925B2 (ro)
KR (2) KR102141323B1 (ro)
CN (3) CN110041304A (ro)
AP (1) AP2014008013A0 (ro)
AR (1) AR090725A1 (ro)
AU (1) AU2013249197B2 (ro)
BR (1) BR112014025972A8 (ro)
CA (2) CA2869893C (ro)
CL (1) CL2014002817A1 (ro)
CO (1) CO7131356A2 (ro)
CR (1) CR20140530A (ro)
CY (1) CY1120276T1 (ro)
DK (2) DK2838892T3 (ro)
DO (1) DOP2014000235A (ro)
EA (1) EA031581B1 (ro)
EC (1) ECSP14027739A (ro)
ES (2) ES2658862T3 (ro)
GE (1) GEP20186902B (ro)
HK (2) HK1202863A1 (ro)
HR (1) HRP20180316T1 (ro)
HU (2) HUE050865T2 (ro)
IL (1) IL235064B (ro)
JO (1) JO3353B1 (ro)
LT (1) LT2838892T (ro)
MA (1) MA37524B1 (ro)
MD (1) MD4615C1 (ro)
ME (1) ME02966B (ro)
MX (1) MX354793B (ro)
MY (1) MY170068A (ro)
NI (1) NI201400124A (ro)
NO (1) NO2877697T3 (ro)
NZ (1) NZ700833A (ro)
PE (1) PE20150084A1 (ro)
PH (1) PH12014502351B1 (ro)
PL (2) PL3290410T3 (ro)
PT (2) PT3517532T (ro)
RS (1) RS56869B1 (ro)
SG (2) SG11201406478XA (ro)
SI (2) SI3290410T1 (ro)
TN (1) TN2014000421A1 (ro)
TW (2) TWI589572B (ro)
UA (1) UA116207C2 (ro)
UY (1) UY34753A (ro)
WO (1) WO2013158874A1 (ro)
ZA (1) ZA201408508B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
US9675600B2 (en) * 2014-09-04 2017-06-13 Helsinn Healthcare Sa Medical treatments based on anamorelin
EP3324958B1 (en) 2015-07-24 2021-07-28 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
EP4021419A1 (en) 2019-08-30 2022-07-06 Helsinn Healthcare SA Methods of manufacturing anamorelin tablets having improved stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
CA2572325C (en) 2004-06-29 2013-08-27 Sapphire Therapeutics, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
EA201401151A1 (ru) 2015-06-30
TW201348224A (zh) 2013-12-01
BR112014025972A8 (pt) 2021-06-22
HK1202863A1 (en) 2015-10-09
US10300105B2 (en) 2019-05-28
CR20140530A (es) 2015-03-25
EP2838892B1 (en) 2017-12-06
MX2014012178A (es) 2015-08-05
US9981002B2 (en) 2018-05-29
CL2014002817A1 (es) 2015-08-14
US20140018391A1 (en) 2014-01-16
CN110041304A (zh) 2019-07-23
BR112014025972A2 (pt) 2017-06-27
AU2013249197B2 (en) 2017-04-06
SI3290410T1 (sl) 2020-11-30
PL3290410T3 (pl) 2021-01-11
JP2017101082A (ja) 2017-06-08
JP6284665B2 (ja) 2018-02-28
MA37524B1 (fr) 2017-04-28
DK2838892T3 (en) 2018-03-12
DK3517532T3 (da) 2022-01-03
TWI589572B (zh) 2017-07-01
CA2869893C (en) 2019-03-05
US20190231843A1 (en) 2019-08-01
UA116207C2 (uk) 2018-02-26
HUE035697T2 (en) 2018-05-28
AP2014008013A0 (en) 2014-10-31
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
UY34753A (es) 2013-11-29
CN110041398A (zh) 2019-07-23
US20200276259A1 (en) 2020-09-03
SI2838892T1 (en) 2018-05-31
NO2877697T3 (ro) 2018-10-13
US20190000914A1 (en) 2019-01-03
SG10201608488RA (en) 2016-12-29
US10576122B2 (en) 2020-03-03
ME02966B (me) 2018-07-20
CN103857669B (zh) 2019-06-28
US20160237115A1 (en) 2016-08-18
US20150072934A1 (en) 2015-03-12
JP6616853B2 (ja) 2019-12-04
NI201400124A (es) 2015-09-21
US9403867B2 (en) 2016-08-02
JP2015514779A (ja) 2015-05-21
US10905737B2 (en) 2021-02-02
ES2658862T3 (es) 2018-03-12
CY1120276T1 (el) 2019-07-10
PL2838892T3 (pl) 2018-05-30
HK1248694A1 (zh) 2018-10-19
PE20150084A1 (es) 2015-01-23
CA2869893A1 (en) 2013-10-24
IL235064B (en) 2019-09-26
PT3517532T (pt) 2021-11-08
US20160235804A1 (en) 2016-08-18
NZ700833A (en) 2016-01-29
US20160229889A1 (en) 2016-08-11
MA37524A1 (fr) 2016-06-30
LT2838892T (lt) 2018-03-12
PH12014502351A1 (en) 2015-01-12
RS56869B1 (sr) 2018-04-30
HRP20180316T1 (hr) 2018-04-06
PH12014502351B1 (en) 2015-01-12
EP2838892A1 (en) 2015-02-25
CN103857669A (zh) 2014-06-11
AR090725A1 (es) 2014-12-03
EP3290410A1 (en) 2018-03-07
CO7131356A2 (es) 2014-12-01
TWI677494B (zh) 2019-11-21
ECSP14027739A (es) 2015-12-31
MX354793B (es) 2018-03-21
TW201722928A (zh) 2017-07-01
SG11201406478XA (en) 2014-11-27
AU2013249197A1 (en) 2014-10-30
CA3031652C (en) 2020-10-27
MD4615C1 (ro) 2019-08-31
EP3517532B1 (en) 2021-10-13
JP6109925B2 (ja) 2017-04-05
KR101972998B1 (ko) 2019-04-29
KR102141323B1 (ko) 2020-08-05
EP3517532A1 (en) 2019-07-31
DOP2014000235A (es) 2015-01-31
ES2820354T3 (es) 2021-04-20
KR20150013115A (ko) 2015-02-04
MY170068A (en) 2019-07-03
KR20190044697A (ko) 2019-04-30
GEP20186902B (en) 2018-10-25
EP3290410B1 (en) 2020-07-01
TN2014000421A1 (en) 2016-03-30
JO3353B1 (ar) 2019-03-13
HUE050865T2 (hu) 2021-01-28
IL235064A0 (en) 2014-12-31
JP2018076375A (ja) 2018-05-17
WO2013158874A1 (en) 2013-10-24
PT2838892T (pt) 2018-02-28
US9956261B2 (en) 2018-05-01
US9872883B2 (en) 2018-01-23
EA031581B1 (ru) 2019-01-31
CA3031652A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
IL266301A (en) Antecedents of glutarimide, their use, a pharmaceutical preparation based on them and methods for producing antecedents of glutarimide
MX2013010360A (es) Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
UA111186C2 (uk) Способи та композиції для одержання норибогаїну з воакангіну
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
UA115357C2 (uk) Похідні піридин-4-ілу
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MD20140122A2 (ro) Procedee de producere a clorhidratului de anamorelin cu un conţinut controlat de clorură
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IN2015DN02660A (ro)
IN2013CH05769A (ro)
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.

Legal Events

Date Code Title Description
FG4A Patent for invention issued